Quinoline Derivative Near-Infrared Fluorescent Probes for Tau Aggregates
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic methods for tauopathy, particularly Alzheimer's disease, face limitations due to the low specificity of beta-amyloid probes and the use of radioactive isotopes, which are costly and invasive, while near-infrared fluorescence detection has not been effectively utilized for early-stage diagnosis.
Innovation Solution
A novel quinoline derivative compound with high selectivity for tau aggregates is developed, forming a near-infrared fluorescent probe that selectively binds to tau fiber proteins, enabling early diagnosis of tauopathy through a non-invasive, cost-effective method.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If beta-amyloid probes are used for diagnosis, then Alzheimer's disease can be detected, but the probes have low specificity and are of limited usefulness
Solution Approach 1:
The patent changes the target parameter from beta-amyloid to tau protein aggregates, which provides higher diagnostic specificity for Alzheimer's disease. The quinoline derivative compounds are specifically designed to bind to tau aggregates rather than beta-amyloid, fundamentally changing the detection target to achieve better diagnostic reliability
Solution Approach 2:
The patent creates a fluorescent copy of tau aggregates using quinoline derivative compounds that bind to and visualize tau protein aggregates. This fluorescent labeling approach allows indirect detection of tau aggregates through fluorescence signals, providing a reliable diagnostic method with high specificity
2Extent of automation
If PET imaging with radioisotope probes is used, then molecular imaging can be performed, but it requires special facilities, equipment, and incurs high costs
Solution Approach 1:
The patent replaces the complex radioisotope-based PET imaging system with a simpler fluorescence imaging system using quinoline derivative compounds. This substitution eliminates the need for expensive radioisotope production facilities, specialized PET scanners, and complex handling procedures, making molecular imaging more accessible and cost-effective
Solution Approach 2:
The patent uses stable, non-radioactive quinoline derivative fluorescent probes instead of expensive, short-lived radioisotopes. These fluorescent compounds can be synthesized routinely without requiring specialized nuclear medicine facilities, significantly reducing the cost and complexity of molecular imaging while maintaining diagnostic capability
3Ease of operation
If near-infrared fluorescence detection is used, then non-invasive real-time diagnosis is enabled, but it has not been effectively utilized for early-stage Alzheimer's diagnosis
Solution Approach 1:
The patent enhances the local quality of near-infrared fluorescent probes by incorporating quinoline derivatives with optimized molecular structures that specifically recognize tau aggregates. This structural optimization improves the binding affinity and fluorescence signal intensity, enabling sensitive detection of early-stage tau aggregation while maintaining the advantages of non-invasive real-time imaging
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The quinoline derivative compound effectively detects tau aggregates, providing a sensitive and specific diagnostic tool for tauopathy, including Alzheimer's disease, without the need for radioactive isotopes, allowing for early detection and monitoring of disease progression.
Implementation Method 1
near-infrared fluorescent probe selectively binds to tau fiber proteins, enabling early diagnosis of tauopathy
Data Source
AI summary
Disclosed are a compound with near-infrared fluorescence that selectively binds to tau aggregates, a method for preparing the same, a tau-targeting near-infrared fluorescent probe including the compound, a composition for detecting a tau fiber protein containing the near-infrared fluorescent probe as an active ingredient, and the use of the composition for the diagnosis of tauopathy. In particular, the compound does not bind to an amyloid beta protein and has high selectivity to a tau aggregate, specifically reported as an etiology of the initial state of tauopathy, thus being useful as a near-infrared fluorescent detector for detecting a tau fiber protein for early diagnosis of a tauopathy including Alzheimer's disease.